Patent Application
20100151530
This invention refers to fermentation of Escherichia coli cells for the production of plasmid DNA (pDNA), in particular for use in gene therapy and DNA vaccination.
The requirement for fermentation of pDNA on a manufacturing scale has come up due to the clinical success of gene therapy and DNA vaccination during the last decade.
Gene therapy is the treatment or prevention of disease by the administration, delivery and expression of genes in mammalian cells. The ultimate goal of gene therapy is to cure both inherited and acquired disorders by adding, correcting, or replacing genes. Basically, there are two types of gene therapy vectors to achieve these goals, i.e. viral vectors based on inactivated viruses and non-viral vectors based on plasmid DNA. The present invention relates to the production of non-viral plasmid DNA.
Since it was demonstrated that intramuscular injection of pDNA encoding an antigen elicits both a humoral and a cellular immune response, naked plasmid DNA has become of particular importance.
The efficiency of a fermentation process for manufacturing plasmid DNA is characterized by a high yield of pDNA, either per volume fermentation broth (volumetric yield) or per biomass aliquot (specific yield). In the meaning of the present invention, yield is the concentration of plasmid DNA per volume or cell weight. Beyond being obtainable in high yields, the plasmid has to be present in its intact, covalently closed circular (ccc) or supercoiled form. In the meaning of the invention, the percentage of ccc form is termed “plasmid homogeneity”. The concentration of other plasmid forms such as open circular (oc), linear and dimeric or multimeric forms, should be reduced to a minimum in the purified plasmid bulk, and are consequently not desired during fermentation.
Therapeutic plasmids contain three essential parts, i.e. the therapeutic gene under the control of a eukaryotic promoter, mostly the cytomegalovirus (CMV) promoter, an origin of replication (ori) for the autonomous propagation in the prokaryotic cell, and a selection marker, usually an antibiotic resistance gene. The therapeutic gene is selected in view of its clinical and medicinal relevance, while both the ori and the selection marker play a crucial role in plasmid production, especially during fermentation. For constructing a therapeutic plasmid, a key factor is the choice of an origin of replication that replicates to a high number of plasmid copies per cell. Most therapeutic vectors bear the ColE1-type ori. Plasmids having a ColE1 origin derived from pBR322 may reach copy numbers of 50-100 plasmids per cell; plasmids derived from pUC can reach copy numbers of several hundred.
The antibiotic selection marker and the use of antibiotics are necessary during transformation and selection of plasmid harboring cells. However, antibiotic selection pressure should be avoided during industrial manufacturing. It is therefore desirable to develop fermentation processes allowing a stable propagation of the vector without plasmid loss.
The choice of the bacterial host strain has been shown to be a key factor that needs to be considered for fermentation of pDNA. Desirable host phenotypes have the ability to grow to a high cell density, to achieve high plasmid copy numbers, to generate a minimum of plasmid-free cells, to have a minimum potential for genetic alterations of the plasmid, to produce plasmids that are predominantly supercoiled, and to be compatible with common purification procedures.
Although most strains of E. coli are, in principle, suitable for propagating pDNA, the choice of the specific host strain has been shown to have significant impact on the yield and quality of the recovered plasmids (Schoenfeld et al., 1995; Schleef, 1999). Currently, there is no consensus on the genotypic or phenotypic characteristics that would be ideal for bacterial strains used for manufacturing pDNA; there is little published work on optimizing host strains for the purpose of pDNA manufacturing and no data are available from comparative studies that would show the behavior of different strains in controlled fermentations. Since the properties of a host strain sometimes depend on the plasmid of interest, empirical evaluation of several hosts may, when using different plasmids, give substantially different results (Durland and Eastman, 1998).
The phenotype that a strain shows is the result of its particular genotype, i.e. the mutations of specific genes it has. A number of genetic mutations have been suggested that may have an impact on manufacturing of pDNA (Durland and Eastman, 1998). Desirable genotypes include markers that ensure the structural integrity of the plasmid or such which increase the yield due to enhanced plasmid replication.
E. coli DH5α is a frequently used strain or fermentation of plasmid DNA (O'Kennedy et al., 2003; WO 02/064752; O'Kennedy et al., 2000; WO 99/61633). With this strain, high volumetric yields of pDNA (ranging between 70 and 230 mg/L) with a high homogeneity (>90% supercoiled) were obtained (WO 02/064752; WO 99/61633). However, O'Kennedy et al. (2003) showed that, depending on the fermentation strategy, pDNA isolated from DH5α was consistently only 50 to 70% supercoiled. A low degree of superhelicity was also observed with the strain DH10B. Although a high pDNA yield between 100 and 220 mg/L was shown in fed-batch fermentation, the formation of open circular or concatenated (dimeric, multimeric) plasmid forms are reported for plasmid DNA obtained from E. coli DH10B (Lahijani et al., 1996; Chen et al., 1997).
Other strains have been investigated in view of increasing the yield of pDNA, however, without being considered for manufacturing of plasmid DNA for therapeutic use (such as E. coli CP79 and CP143 (Hofmann et al., 1990) or E. coli HB101 (Reinikainen, 1989).
Since regulatory authorities demand supercoiled pDNA for consistency and therapeutic reasons (CBER (1996); WHO (1998); EMEA (2001)), a host that produces a substantial amount of plasmid in a form other than its supercoiled form is disadvantageous.
A further important issue in fermentation of plasmid DNA, which is influenced by the host strain, is the content of pDNA in the harvested biomass, i. e. the specific pDNA yield. Typical specific plasmid yields according to the current state of the art range between 2 and 10 mg per gram dry cell weight. Since buffer volumes for alkaline lysis are based on a certain biomass aliquot, a high specific pDNA yield is particularly advantageous during purification of pDNA—a high specific pDNA concentration will require lower buffer volumes and result in increased pDNA concentrations in the lysis bulk and shorter process times.
Consequently, there is a need for identifying bacterial hosts that have the ideal properties for pDNA production.
The invention relates to the use of Escherichia coli K-12 strain JM108 (in the following termed “JM108”), or a derivative of this strain, as a host strain for the fermentation of plasmid DNA, in particular therapeutic plasmid DNA, on a manufacturing-scale.
The advantageous properties of JM108 or a derivative thereof are independent of the fermentation process. In the experiments of the invention, the superiority of JM108 was shown for different fermentation modes (batch and fed-batch fermentation; use of defined and semi-defined medium).
The use of JM108 or a derivative thereof in manufacturing of pDNA is not restricted to a certain plasmid type, it may be combined with any plasmid. Preferably, plasmids with a pUC origin of replication are used.
E. coli strain K-12 JM108 (ATCC No. 47107; DSMZ No. 5585) is a direct progeny of E. coli JM106, which is derived from the strain DH1. JM108 was originally intended as a host for cosmid libraries (Yanisch-Perron et al., 1985). JM108 has the following genetic markers (i. e. specific mutations): F−, recA1, endA1, gyrA96, thi-1, hsdR-17, supE44, relA1, λ− and Δ(lac-proAB) (Yanisch-Perron et al., 1985).
Thus, JM108 has a defect in the recombination protein RecA and lacks the restriction enzyme endonuclease A (EndA), as well as a part of the type III restriction-modification system (HsdR). Furthermore, JM108 has a mutation in the relA gene. This gene is responsible for the synthesis of guanosine tetraphosphate (ppGpp), a signal molecule which triggers the so-called stringent response in the cell upon amino acid limitation. The genetic marker gyrA96 represents a mutation in the DNA-gyrase (topoisomerase II), an enzyme which influences the supercoiling state of DNA.
Since JM108 has been generated, it has only rarely been used for molecular biology purposes. Its applications were in recombinant protein expression (Herman and McKay, 1986; Riegert et al., 1998), preparation of cosmid libraries (Kakinuma et al., 1991; Omura et al., 2001) and transposon-facilitated DNA sequencing (Ikeda et al., 1999). In a laboratory-scale comparison of ten E. coli strains, no obvious superiority of JM108 was observed (Schleef, 1999).
In the experiments of the invention, JM108 was tested, together with other candidate strains, as a host strain for pDNA production. It was surprisingly found that JM108 has the ability to produce an extraordinarily high yield of pDNA, both in terms of volume and specificity. A special feature of JM108, as compared to other strains, is that plasmids in the bacterial biomass accumulate at a much higher rate. In addition, plasmid homogeneity (% ccc, supercoiled) is consistently high at more than 90% of the ccc form. Furthermore, degradation of ccc pDNA does not occur towards the end of fermentation, as it is the case with strains used in the art. These surprising properties make JM108 an ideal host for pDNA manufacturing, which is superior in its performance compared to state of the art host strains.
Since the mutations of JM108 are not unique for JM108 (for instance, it shares the markers recA, endA, gyrA, and relA with the strains DH1, DH5, DH5α and XL1-blue, and, additionally, the marker hsdR with DH1, DH5 and DH5α), the good performance of JM108 is surprising, it could not be predicted and cannot be explained simply by its mutations.
The present invention relates to a method for producing plasmid DNA on a manufacturing scale by fermenting Escherichia coli cells that contain a plasmid carrying a gene of interest, wherein said cells are cells of the Escherichia coli K-12 strain JM108 or a derivative thereof.
According to the invention, the term “fermentation” relates to the cultivation of host cells in a controlled industrial fermenter (bioreactor) according to methods known in the biopharmaceutical industry. The use of JM108 in fermentation to produce large amounts plasmid DNA results in a performance that is superior to the use of current state-of-the-art E. coli host strains. Manufacturing of pDNA is typically accomplished by performing fermentations in large volumes. The term “manufacturing” and “manufacturing scale” in the meaning of the invention defines a fermentation with a minimum volume of 5 L culture broth.
It was found that JM108 consistently shows both a volumetric and specific pDNA yield that exceeds the results reported from fermentations of other strains.
The high specific pDNA yield obtained by the method of the invention is not only beneficial for fermentation productivity, but also for the subsequent alkaline cell lysis. The reason for this is that buffer volumes for alkaline lysis are always based on a biomass aliquot. A high plasmid content in the biomass (i. e. less biomass with the same plasmid amount) therefore results in a higher plasmid concentration of the alkaline lysate and reduced bulk volumes.
Furthermore, the homogeneity of plasmids obtained from fermentations using JM108 was found to be outstandingly high, with a yield of ≧90% in the supercoiled form. The plasmid showed no or only a weak tendency to decrease towards the end of fermentation. These surprising findings make JM108 an ideal host strain for industrial pDNA production.
In the meaning of the invention, the “JM108” relates to the JM108 strain as such, which is defined by the following genotype: F−, recA1, endA1, gyrA96, thi-1, hsdR-17, supE44, relA1, λ− and Δ(lac-proAB). The definition of “JM108 derivative” in the meaning of the present invention encompasses any E. coli strain that has been obtained by genetically modifying JM108 cells. The JM108 derivative may have one or more additional defined or undefined mutations, e.g. a complete or partial deletion or a disruption of one or more genes, and/or carry one or more additional genes. JM 108 derivatives can be obtained from JM108 according to standard methods, e.g. by insertion and/or inactivation of a gene, as described by Datsenko and Wanner, 2000.
The application of E. coli JM108 or a derivative thereof for pDNA production is not restricted with respect to the fermentation mode, which may be a batch process or a fed-batch process.
In a first embodiment, the method of the invention is carried out in the batch mode.
A batch process is a fermentation mode in which all the nutrients necessary for cultivation of the cells are contained in the culture medium, with no additional supply with nutrients during fermentation. Examples for batch fermentation processes which are useful in the invention are given in Lahijani et al., 1996; O'Kennedy et al., 2003; and WO 02/064752. In such batch processes, plasmid-harboring E. coli cells (the known processes use DH5α or DH10B), are cultivated in controlled fermenters until a certain biomass level is reached, they have been shown to reach from 2.6 to 22 g dry cell weight per liter. The applied culture media may either be chemically defined (as described in WO 02/064752) or semi-defined (Lahijani et al., 1996; O'Kennedy et al., 2003), with no additional nutrient compounds being fed during fermentation. The plasmid yield of the previously described batch processes ranged from 8.5 to 68 mg/L.
In another embodiment, the method of the invention is carried out as a fed-batch process. In a fed-batch process, after a batch cultivation phase, additional nutrients are supplied (fed) to the culture to obtain a higher biomass. The fed-batch process is not restricted with regard to a particular feeding mode. Feeding of nutrients may be done in a continuous or discontinuous mode. The feeding mode may be pre-defined following a time profile, e.g. linear constant, linear increasing, step-wise increasing or exponential (Lahijani et al., 1996; O'Kennedy et al., 2003; WO 96/40905). In another embodiment of the invention, a feedback algorithm may be applied that depends on pre-determined parameters, for instance dependent on biomass, dissolved oxygen (WO 99/61633) or on pH and dissolved oxygen (Chen et al., 1997).
The application of E. coli JM108 or s derivative thereof for pDNA production is not restricted with regard to the type of the culture medium that is used during fermentation. The culture medium may be semi-defined, containing complex media compounds (e.g. yeast extract, soy peptone, casamino acids) or may be chemically defined, without complex compounds.
The use of E. coli JM108 or a derivative thereof is neither restricted to a certain plasmid or plasmid type, nor to the purpose of the plasmid, which is defined by the gene of interest, e.g. a therapeutic gene. In a preferred embodiment, the plasmids to be produced by fermenting JM108 or a derivative thereof according to the method of the invention are intended for use in gene therapy or DNA vaccination.
Plasmids suitable for application in the invention are for example derived from pBR322, pUC18, pUC19, pcDNA3 (Invitrogen).
In a preferred embodiment of the invention, a plasmid having a ColE1 origin of replication is used. The advantage of ColE1 plasmids is that, upon amino acid limitation, uncharged transfer RNAs (tRNAs) interact with the ColE1 replication origin, which results in an enhanced replication rate of the plasmid (Wrobel and Wergrzyn, 1998).
In a preferred embodiment of the invention, a ColE1-derived plasmid of the pUC type (originally described by Vieira and Messing, 1982, Yanisch-Perron et al., 1985) is used. The pUC plasmids have a mutation in the copy number-decreasing protein Rom, which results in a higher plasmid copy number than obtained with the original ColE1 type plasmid. Since the replication-enhancing effect of rom-plasmids has been shown to especially occur at low specific growth rates (Atlung et al., 1999), the combination of pUC plasmids with cultivation at a low specific growth rate, e.g. ca. 0.05 to 0.15 h−1 is preferred in the invention.
Plasmid DNA obtained according to the method of the invention by cultivation of E. coli JM 108 or a derivative thereof is recovered and purified according to known methods. Plasmid purification typically starts with the disintegration of the harvested cell mass, usually by alkaline lysis. Thereby, cells are subjected to high alkaline pH values together with detergents, so that the cells are lysed and the plasmids are released. Upon the following precipitation step with acetate buffer, proteins and genomic DNA get precipitated, whereas the plasmid DNA remains in the clarified supernatant. The subsequent purification steps comprise mainly filtration (ultrafiltration, diafiltration) and chromatographic techniques. The chromatographic methods may be selected from, for example, hydrophobic interaction, ion exchange or gel filtration chromatography.
Preliminary Experiment 1
Shake Flask Cultivation of Different E. coli Host Strains Harboring Three Different Plasmids
In this experiment, several plasmid bearing host strains were compared in a typical lab-scale cultivation. In 100 mL baffled shake flasks containing 40 mL modified LB medium (10 g/L soy peptone; 5 g/L yeast extract; 10 g/L NaCl), seven different plasmid harboring E. coli strains were cultivated until early stationary phase (37° C., rotary shaker 300 rpm). The strains harbored the therapeutic plasmids pRZ-hMCP1 (4.9 kb, coding for human monocyte chemoattractant protein 1, (Furutani et al. (1989), pGS-hil2-tet (4.3 kb; coding for human interleukin 2) and pRZ-hGM-CSF (5.4 kb; coding for human granulocyte monocyte colony stimulating factor). The cultivations were characterized in terms of growth (optical density, OD550), volumetric plasmid yield (mg pDNA/L), specific plasmid yield (mg/OD*L) and plasmid homogeneity (% supercoiled, ccc).
For pDNA analysis, cell aliquots were lysed by a modified alkaline lysis method as originally described by Birnboim and Doly (1979) and the pDNA yield and homogeneity was determined by anion exchange high performance chromatography (Tosoh Biosep DNA-NPR-DEAE column; equilibration and load with 20 mM Tris at pH 9; separation and gradient elution with 20 mM Tris containing 1 M NaCl; flow rate 0.8 mL/min at 25° C.; detection of pDNA with UV diode array detector at 260 nm). This analytical method was also applied for all pDNA analysis in the other examples presented here.
Preliminary Experiment 2
Batch Fermentations of Different E. coli Host Strains Harboring the Plasmid pRZ-hMCP1 in a Semi-Defined Medium (1 L-Scale)
In 1 L-scale fermenters, with nine strains harboring the plasmid pRZ-hMCP1 (4.9 kb, pUC ori, kanamycin resistance, coding for human monocyte chemoattractant protein 1 under the control of the eucaryotic CMV promoter), batch fermentations with a semi-defined culture medium were carried out. This example shall demonstrate the superiority of JM108 compared to other host strains.
For preculture, a shake flask containing 200 mL medium, was inoculated with 1 mL of a glycerol stock of the respective strain and cultivated in a rotary shaker (37° C., 300 rpm) until an optical density of 1-1.5 was obtained. The preculture medium consisted of 13.5 g/L soy peptone; 7 g/L yeast extract; 6 g/L glycerol; 2.5 g/L NaCl; 2.3 g/L K2HPO4; 1.5 g/L KH2PO4; and 0.25 g/L MgSO4*7H2O. The preculture was inoculated into the fermenters (1% v/v of batch medium) which contained a medium of the following composition: 13.5 g/L soy peptone; 7 g/L yeast extract; 15 g/L glycerol; 0.5 g/L trisodium citrate; 1.2 g/L KH2PO4; 2.2 g/L Na2HPO4*12H2O; 5 g/L (NH4)2SO4; 4 g/L NH4Cl; 0.8 g/L MgSO4*7H2O; 0.26 g/L CaCl2*2H2O; 1.5 ml/L trace element solution; and 5 mL/L thiamin hydrocloride solution (1%). The trace element solution contained: 27 g/L FeCl3*6H2O; 8 g/L ZnSO4*7H2O; 7 g/L CoCl2*6H2O; 7 g/L MoNa2O4*2H2O; 8 g/L CuSO4*5H2O; 2 g/L H3BO3; and 5 g/L MnSO4*7H2O. The cultivation temperature was 37° C. and the pH was controlled at 7.0 with 25% w/v NaOH and 25% w/v H2SO4. A dissolved oxygen tension (DOT) of ≧20% saturation was maintained with a constant aeration rate of 1 vvm and if necessary, by the increase of the agitation rate (500-1000 rpm). The cultivations were terminated when the culture was in the stationary growth phase for 3-4 h, determined by measuring the optical density.
Table 1 shows the results of these fermentations. Although JM108 grew only to a low biomass, the volumetric plasmid yield was highest with 112 mg pDNA/L. This is an advantage for plasmid DNA production, since low amounts of biomass simplify large scale alkaline lysis during downstream processing. This reduced growth activity resulted in the extraordinary high specific pDNA yield of 8.2 mg/OD*L (which corresponds to approximately 30 mg pDNA/g dry cell weight).
E. coli host strain
In
Batch Fermentation of E. coli JM108 (pRZ-hMCP1) in a Semi-Defined Medium on Different Manufacturing Scales
Fermentations were carried out on a manufacturing scale of 20 L and 200 L, in the same way as described in Example 2. It is shown in Table 2 that on both manufacturing scales, a high volumetric and specific yield was obtained. Moreover, pDNA homogeneity was consistently ≧90% of supercoiled form. This example shows that the application of JM108 is not restricted to a certain fermentation scale.
In
Preliminary Experiment 3
Batch Fermentation of E. coli JM108 Harboring the Plasmid pRZ-hMCP1 in a Chemically Defined Medium
A batch fermentation was carried out in a 1 L scale fermenter with the E. coli JM108 harboring the plasmid pRZ-hMCP1. For a preculture, a glycerol stock of the strain (300 μL) was inoculated into a baffled 1000 mL shake flask containing 300 mL of a defined medium. This was cultivated in a rotary shaker at 300 rpm and 37° C. The preculture medium was composed as follows: NH4Cl 2 g/L, MgSO4*7H2O 0.24 g/L, glucose 10 g/L, L-proline 0.2 g/L, L-isoleucine 0.2 g/L, thiamine hydrochloride 1 mg/L, citric acid 2 g/L, KH2PO4 5.44 g/L, Na2HPO4*12H2O 14.38 g/L and trace element solution 16.7 mL/L The trace element solution contained HCl (25%) 14.6 g/L, CaCl2*2H2O 0.44 g/L, FeSO4*7H2O 0.33 g/L CoCl2*6H2O 0.14 g/L, MnSO4*H2O 0.10 g/L, CuSO4*5H2O 15 mg/L and ZnSO4*7H2O 17 mg/L. As the pre-culture has reached an optical density of approximately OD=1, it was transferred into the fermenter and the fermentation was started. The main culture batch medium was composed of the same components with the same concentrations as present in the pre-culture. The temperature was controlled at 37° C. The fermenter was aerated with a process air mass flow rate of 1 vvm (volume air per volume medium and minute). When the dissolved oxygen tension dropped down to 30%, it was maintained at this set point by increasing the agitation rate of the stirrer (500-1000 rpm). The pH was controlled at the set point of 7.0 with a solution of ammonium hydroxide (25%) and 25% H2SO4.
As the culture had entered the stationary growth phase, the cultivation was extended for additional 20 h to observe the course of plasmid replication and plasmid homogeneity.
Fed-Batch Fermentation of E. coli JM108 (pRZ-hMCP1) in a Semi-Defined Medium by Applying an Exponential Feeding Algorithm
A fed-batch fermentation was carried out by first cultivating the strain JM108 in a semi-defined batch medium as described in Preliminary Experiment 2, followed by feeding according to an exponential function upon the batch phase. The scale was 20 L culture broth volume at the end of the fermentation. The preculture and the batch cultivation phase were identical as in Example 2, with the same media composition and the same cultivation conditions. After 12 h of batch cultivation, the feed was initiated in order to control the specific growth rate μ at the value of 0.1 h-1. The volume of feed medium to be added after a certain time point (Vt) was calculated according to the following function:
In this function, Vt is the volume [L] of feed medium to be added at the time distance t [h] calculated from the start of the feed. X0 is the total amount of biomass dry cell weight [g] at the time point of start feed. YX/S is the biomass yield coefficient (g dry cell weight per g substrate) and CS is the concentration of the substrate (glycerol as organic carbon source) in the feed medium [g/L]. The specific growth rate μ [h−1] was set at the value of 0.1 h−1. The biomass yield coefficient was estimated as 0.25 g biomass per g glycerol. The biomass amount at the start of feeding X0 was estimated by measurement of the optical density at the time point of start feeding.
The feed medium was a concentrated solution of all necessary nutrients and was composed as follows: 83 g/L soy peptone; 42 g/L yeast extract; 250 g/L glycerol; 1.4 g/L trisodium citrate; 3.4 g/L KH2PO4; 6.2 g/L Na2HPO4*12H2O; 14.2 g/L (NH4)2SO4; 11.3 g/L NH4Cl; 2.3 g/L MgSO4*7H2O; 0.7 g/L CaCl2*2H2O; 14.2 mL/L thiamin hydrocloride solution (1%) and 4.3 ml/L trace element solution, composed as described in Example 2.
As shown in
Fed-Batch Fermentation of E. coli JM108 Carrying the Plasmid pRZ-hMCP1 (20 L Fermenter) by Using a Chemically Defined Culture Medium and an Exponential Feeding Algorithm
An exponential fed-batch fermentation was carried out in a 20 L scale fermenter with E. coli JM108 harboring the plasmid pRZ-hMCP1 in a process using a chemically defined culture medium (i. e. without complex medium compounds).
For a pre-culture, a glycerol stock of the strain (300 μL) was inoculated into a baffled 1000 mL shake flask containing 300 mL of a defined medium. This was cultivated in a rotary shaker at 300 rpm and 37° C. The preculture medium was composed as described in Example 4. When the preculture had reached an optical density of approximately OD550=1, it was transferred into the fermenter and the fermentation was started. The main culture batch medium was composed of the same components with the same concentrations as present in the preculture. The fermenter contained 7 L of batch medium at the onset of the fermentation. The temperature was controlled at 37° C. and the fermentation was operated with a back pressure of 0.35 bar. The fermenter was aerated with a process air mass flow rate of 1 vvm (volume air per volume medium and minute=7 L/min) When the dissolved oxygen tension dropped down to 30%, it was maintained at this set point by increasing the agitation rate of the stirrer (500-1000 rpm). In case the increase of the agitation rate was not sufficient to maintain the DO, the oxygen concentration of the air was enriched with pure oxygen. The pH was controlled at the set point of 7.0±0.2 with a solution of ammonium hydroxide (25%), which concomitantly served as source of nitrogen throughout the fermentation. If necessary, the pH was further controlled with 25% H2SO4.
After 10 h of batch cultivation, glucose in the batch medium was used up. This was determined with a rapid off-line measurement method (Yellow Springs Glucose Analyzer, YSI 2700 Select). The depletion of glucose served as the signal for the start of the exponential feeding phase. Continuous exponential feeding was controlled via the process control system of the fermenter, based on biomass at the time point of glucose depletion (estimated via optical density). The feed medium was composed as follows: glucose 300 g/L; MgSO4*7H2O 7.2 g/L; L-proline 6 g/L; L-isoleucine 6 g/L; thiamine hydrochloride 30 mg/L; citric acid 2 g/L; KH2PO4 5.4 g/L; Na2HPO4*12H2O 14.4 g/L; CaCl2*2H2O 220 mg/L; FeSO4*7H2O 170 mg/L; CoCl2*6H2O 72 mg/L, MnSO4*H2O 51 mg/L, CuSO4*5H2O 8 mg/L and ZnSO4*7H2O 9 mg/L. The feeding rate was chosen to obtain a pre-defined specific growth rate μ of 0.1 h−1. The calculation of the feeding rate was accomplished in a similar way as described in Example 5.
In
This example shows that the strain JM108 is superior compared to state-of-the-art host strains in terms of pDNA yield and homogeneity, in particular when a defined medium is used, in combination with exponential feeding.
Comparison of State-of-the-Art E. coli Host Strains with the Strain JM108 in Plasmid Fermentation
In Table 3, data obtained from the fermentations described in Examples 1 to 3 were compared between prior-art strains and JM108. It could be shown that, in all fermentation processes, JM 108 is superior to the prior-art strains in terms of volumetric and specific yield. In addition, the pDNA homogeneity obtained with JM108 never was below 89% ccc.
| Number | Date | Country | Kind |
|---|---|---|---|
| 04 008 557.3 | Apr 2004 | EP | regional |
This application is a continuation of application Ser. No. 11/101,747 filed Apr. 8, 2005, which claims benefit from U.S. Provisional Application 60/568,844, filed on May 7, 2004, and from international application EP 04 008 557.3, filed Apr. 8, 2004 the contents of which are incorporated herein.
| Number | Date | Country | |
|---|---|---|---|
| 60568844 | May 2004 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 11101747 | Apr 2005 | US |
| Child | 12562420 | US |
